View All Information for Patients & Visitors »

New to MyHealth?

Manage Your Care From Anywhere.

Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.

Activate Your Account with an access code or Create a New Account

MyHealth for Mobile

The MyHealth mobile app puts all your health information at your fingertips and makes managing your health care simple and quick. Available for iPhone and Android.

Robert Negrin

Why I went into Medicine

Robert Negrin, MD: Why I Went into Medicine

Robert Negrin, MD, Director of Stanford's Blood and Marrow Transplant program on why he left biochemistry to become a hematologist.

Robert Negrin

BMT specialist, Hematologist

Professor of Medicine (Blood and Marrow Transplantation)

Summary
Clinical Trials
Reviews

4.9 out of 5

69 Patient Ratings
12 Patient Comments

Blood and Marrow Transplant Program (BMT)

875 Blake Wilbur Drive
Clinic E, 1st Floor
Palo Alto, CA 94304
Phone: 650-723-0822

More Clinic Information » Insurance Coverage »

Hematology Program

875 Blake Wilbur Drive
Clinic C
Palo Alto, CA 94304
Phone: 650-498-6000

More Clinic Information » Insurance Coverage »

Cancer Immunotherapy Program

875 Blake Wilbur Drive
Palo Alto, CA 94304
Phone: 650-498-6000

More Clinic Information » Insurance Coverage »

Summary
Clinical Trials
Reviews

Practice Areas

View All 11 Practice Areas

Professional Education

Residency: Stanford University School of Medicine (1986) CA
Internship: Stanford University School of Medicine (1985) CA
Fellowship: Stanford University School of Medicine (1987) CA
Board Certification: Hematology, American Board of Internal Medicine (1992)
Board Certification: Internal Medicine, American Board of Internal Medicine (1987)
Medical Education: Harvard Medical School (1984) MA
BA, Univ. California, Berkeley, Biochemistry (1977)

View All

Honors & Awards

Associate Editor, Blood (2010-present)
Member, Association of American Physicians (AAP) (2008)
President, American Society of Blood and Marrow Transplantation (2006-2007)
Distinguished Clinical Scientist Award, Doris Duke Foundation (2004-2009)
President, International Society of Cellular Therapy (2000-2002)
Fellow, Jose Carreras International Leukemia Foundation (1993-1996)
Fellowship, Damon Runyon-Walter Winchell Cancer Fund (1988-1991)

View All

Administrative Appointments

Division Chief, Blood and Marrow Transplant Program, Stanford University (2000 - Present)
Medical Director, Clinical Bone Marrow Transplantation Laboratory (1990 - Present)

View All

Publications

Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease
Kurnellas, M. P., Ghosn, E. E. B., Schartner, J. M., Baker, J., Rothbard, J. J., & Rothbard, J. B. (2015). Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 112(49), 15016-15023.
MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.
Buechele, C., Breese, E. H., Schneidawind, D., Lin, C.-H., Jeong, J., & Cleary, M. L. (2015). MLL leukemia induction by genome editing of human CD34+ hematopoietic cells. Blood, 126(14), 1683-1694.
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.
Filatenkov, A., Baker, J., Mueller, A. Ms., Kenkel, J., Ahn, G.-O., & Strober, S. (2015). Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clinical cancer research , 21(16), 3727-3739.
Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease Kim, B.-S., Nishikii, H., Baker, J., Pierini, A., Schneidawind, D., & Negrin, R. S. (2015). Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. BLOOD, 126(4), 546-557.
Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease Pierini, A., Colonna, L., Alvarez, M., Schneidawind, D., Nishikii, H., & Negrin, R. S. (2015). Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease. JOURNAL OF IMMUNOLOGY, 195(1), 347-355.
Unipotent Megakaryopoietic Pathway Bridging Hematopoietic Stem Cells and Mature Megakaryocytes Nishikii, H., Kanazawa, Y., Umemoto, T., Goltsev, Y., Matsuzaki, Y., & Chiba, S. (2015). Unipotent Megakaryopoietic Pathway Bridging Hematopoietic Stem Cells and Mature Megakaryocytes. STEM CELLS, 33(7), 2196-2207.
Third-party CD4(+) invariant natural killer T cells protect from murine GVHD lethality Schneidawind, D., Baker, J., Pierini, A., Buechele, C., Luong, R. H., & Negrin, R. S. (2015). Third-party CD4(+) invariant natural killer T cells protect from murine GVHD lethality. BLOOD, 125(22), 3491-3500.
ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation Logan, A. C., Wang, Z., Alimoghaddam, K., Wong, R. M., Lai, T., & Miklos, D. B. (2015). ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(4), 746-754.
Engraftment of Embryonic Stem Cells and Differentiated Progeny by Host Conditioning with Total Lymphoid Irradiation and Regulatory T Cells Pan, Y., Leveson-Gower, D. B., de Almeida, P. E., Pierini, A., Baker, J., & Negrin, R. S. (2015). Engraftment of Embryonic Stem Cells and Differentiated Progeny by Host Conditioning with Total Lymphoid Irradiation and Regulatory T Cells. CELL REPORTS, 10(11), 1793-1802.
CD4(+) invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4(+)CD25(+)FoxP3(+) regulatory T cells Schneidawind, D., Pierini, A., Alvarez, M., Pan, Y., Baker, J., & Negrin, R. S. (2014). CD4(+) invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4(+)CD25(+)FoxP3(+) regulatory T cells. BLOOD, 124(22), 3320-3328.
Identification of Orai1 Channel Inhibitors by Using Minimal Functional Domains to Screen Small Molecule Microarrays Sadaghiani, A. M., Lee, S. M., Odegaard, J. I., Leveson-Gower, D. B., McPherson, O. M., & Park, C. Y. (2014). Identification of Orai1 Channel Inhibitors by Using Minimal Functional Domains to Screen Small Molecule Microarrays. CHEMISTRY & BIOLOGY, 21(10), 1278-1292.
Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models Florek, M., Sega, E. I., Leveson-Gower, D. B., Baker, J., Mueller, A. Ms., & Negrin, R. S. (2014). Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models. BLOOD, 124(11), 1832-1842.
Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models. Florek, M., Sega, E. I., Leveson-Gower, D. B., Baker, J., Müller, A. Ms., & Negrin, R. S. (2014). Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models. Blood, 124(11), 1832-1842.
Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion Filatenkov, A., Baker, J., Muller, A. M., Ahn, G.-O., Kohrt, H., & Strober, S. (2014). Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion. RADIATION RESEARCH, 182(2), 163-169.
Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.
Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. Müller, A. Ms., Poyser, J., Küpper, N. J., Burnett, C., Ko, R. M., & Shizuru, J. A. (2014). Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. Blood, 123(18), 2882-2892.
Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance de Almeida, P. E., Meyer, E. H., Kooreman, N. G., Diecke, S., Dey, D., & Wu, J. C. (2014). Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. NATURE COMMUNICATIONS, 5.
European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., & Lowsky, R. (2014). European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. BLOOD CANCER JOURNAL, 4.
A killer choice for cancer immunotherapy Schmidt, T. L., Negrin, R. S., & Contag, C. H. (2014). A killer choice for cancer immunotherapy. IMMUNOLOGIC RESEARCH, 58(2-3), 300-306.
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations Giralt, S., Costa, L., Schriber, J., DiPersio, J., Maziarz, R., & Devine, S. (2014). Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(3), 295-308.
Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation Sega, E. I., Leveson-Gower, D. B., Florek, M., Schneidawind, D., Luong, R. H., & Negrin, R. S. (2014). Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation. PLOS ONE, 9(1).
Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. Sega, E. I., Leveson-Gower, D. B., Florek, M., Schneidawind, D., Luong, R. H., & Negrin, R. S. (2014). Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PloS one, 9(1).
Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. de Almeida, P. E., Meyer, E. H., Kooreman, N. G., Diecke, S., Dey, D., & Wu, J. C. (2014). Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nature communications, 5, 3903-?.
Mast cells suppress murine GVHD in a mechanism independent of CD4(+)CD25(+) regulatory T cells Leveson-Gower, D. B., Sega, E. I., Kalesnikoff, J., Florek, M., Pan, Y., & Negrin, R. S. (2013). Mast cells suppress murine GVHD in a mechanism independent of CD4(+)CD25(+) regulatory T cells. BLOOD, 122(22), 3659-3665.
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation Colonna, L., Florek, M., Leveson-Gower, D. B., Sega, E. I., Baker, J., & Negrin, R. S. (2013). IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(11), 1557-1565.
Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation Schneidawind, D., Pierini, A., & Negrin, R. S. (2013). Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. BLOOD, 122(18), 3116-3121.
A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease Meyer, E. H., Hsu, A. R., Liliental, J., Loehr, A., Florek, M., & Negrin, R. S. (2013). A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. BLOOD, 121(24), 4955-4962.
A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model Baeuerlein, C. A., Riedel, S. S., Baker, J., Brede, C., Garrote, A.-L. J., & Beilhack, A. (2013). A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model. BMC MEDICINE, 11.
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells Lask, A., Ophir, E., Or-Geva, N., Cohen-Fredarow, A., Afik, R., & Reisner, Y. (2013). A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells. BLOOD, 121(15), 3033-3040.
Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells Ophir, E., Or-Geva, N., Gurevich, I., Tal, O., Eidelstein, Y., & Reisner, Y. (2013). Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells. BLOOD, 121(7), 1220-1228.
The Expansion of Gastrointestinal-Associated alpha beta T Cell Clones in Peripheral Blood Associates with Severe Steroid Refractory GVHD Meyer, E. H., Liliental, J. A., Florek, M., Lohr, A., Hsu, A., & Negrin, R. (2013). The Expansion of Gastrointestinal-Associated alpha beta T Cell Clones in Peripheral Blood Associates with Severe Steroid Refractory GVHD. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S334-S335.
Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., & Lowsky, R. (2013). Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S154-S155.
TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., & Lowsky, R. (2013). TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S113-S114.
A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model. Bäuerlein, C. A., Riedel, S. S., Baker, J., Brede, C., Garrote, A.-L. J., & Beilhack, A. (2013). A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model. BMC medicine, 11, 134-?.
Cancer Vaccines and T Cell Therapy Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., & Barrett, J. (2013). Cancer Vaccines and T Cell Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(1), S97-S101.
Mapping immune processes in intact tissues at cellular resolution. Brede, C., Friedrich, M., Jordán-Garrote, A.-L., Riedel, S. S., Bäuerlein, C. A., & Beilhack, A. (2012). Mapping immune processes in intact tissues at cellular resolution. journal of clinical investigation, 122(12), 4439-4446.
Mapping immune processes in intact tissues at cellular resolution Brede, C., Friedrich, M., Jordan-Garrote, A.-L., Riedel, S. S., Baeuerlein, C. A., & Beilhack, A. (2012). Mapping immune processes in intact tissues at cellular resolution. JOURNAL OF CLINICAL INVESTIGATION, 122(12), 4439-4446.
Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms. Benjamin, J., Chhabra, S., Kohrt, H. E., Laport, G. G., Arai, S., & Lowsky, R. (2012). Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms. BLOOD, 120(21).
The Expansion of Gastrointestinal-associated alpha beta T Cell Clones in Peripheral Blood Over Time Is a Disease Feature of Severe Acute Graft-Versus-Host Disease Meyer, E. H., Liliental, J., Florek, M., Loehr, A., Hsu, A., & Negrin, R. S. (2012). The Expansion of Gastrointestinal-associated alpha beta T Cell Clones in Peripheral Blood Over Time Is a Disease Feature of Severe Acute Graft-Versus-Host Disease. BLOOD, 120(21).
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells Gill, S., Vasey, A. E., De Souza, A., Baker, J., Smith, A. T., & Negrin, R. S. (2012). Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. BLOOD, 119(24), 5758-5768.
Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity Mueller, A. Ms., Shashidhar, S., Kuepper, N. J., Kohrt, H. Ek., Florek, M., & Shizuru, J. A. (2012). Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(15), 5820-5825.
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516-521.
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow Mielcarek, M., Storer, B., Martin, P. J., Forman, S. J., Negrin, R. S., & Bensinger, W. I. (2012). Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. BLOOD, 119(11), 2675-2678.
Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells Mueller, A. Ms., Kohrt, H. Ek., Cha, S., Laport, G., Klein, J., & Shizuru, J. A. (2012). Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 125-133.
Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation Guerrero, A., Riddell, S. R., Storek, J., Stevens-Ayers, T., Storer, B., & Boeckh, M. (2012). Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 66-75.
Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.
Role of regulatory T cell populations in controlling graft vs host disease Negrin, R. S. (2011). Role of regulatory T cell populations in controlling graft vs host disease. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 24(3), 453-457.
Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4(+)CD25(+)Foxp3(+) regulatory T cells Shin, H.-J., Baker, J., Leveson-Gower, D. B., Smith, A. T., Sega, E. I., & Negrin, R. S. (2011). Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4(+)CD25(+)Foxp3(+) regulatory T cells. BLOOD, 118(8), 2342-2350.
Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response Tomblyn, M. R., Ewell, M., Bredeson, C., Kahl, B. S., Goodman, S. A., & Laport, G. G. (2011). Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(7), 1051-1057.
Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism Leveson-Gower, D. B., Olson, J. A., Sega, E. I., Luong, R. H., Baker, J., & Negrin, R. S. (2011). Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. BLOOD, 117(11), 3220-3229.
CD8(+)CD44(hi) but not CD4(+)CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD Dutt, S., Baker, J., Kohrt, H. E., Kambham, N., Sanyal, M., & Strober, S. (2011). CD8(+)CD44(hi) but not CD4(+)CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. BLOOD, 117(11), 3230-3239.
Short-Term Immunosuppression Promotes Engraftment of Embryonic and Induced Pluripotent Stem Cells Pearl, J. I., Lee, A. S., Leveson-Gower, D. B., Sun, N., Ghosh, Z., & Wu, J. C. (2011). Short-Term Immunosuppression Promotes Engraftment of Embryonic and Induced Pluripotent Stem Cells. CELL STEM CELL, 8(3), 309-317.
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.
KINETICS OF MURINE GVHD INDUCTION ACROSS MINOR AND MAJOR HISTOCOMPATIBILITY BARRIERS Vasey, A. E., Baker, J. B., Leveson-Gower, D. B., & Negrin, R. S. (2011). KINETICS OF MURINE GVHD INDUCTION ACROSS MINOR AND MAJOR HISTOCOMPATIBILITY BARRIERS. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(2), S340-S340.
SINGLE DOSE ADMINISTRATION OF ECP TREATED CELLS PRIOR TO TRANSPLANTATION SIGNIFICANTLY INCREASES SURVIVAL IN A MHC-MISMATCHED MODEL OF ACUTE GVHD Florek, M., Sega, E. I., Leveson-Gower, D. B., Gill, S., Mueller, A. Ms., & Negrin, R. S. (2011). SINGLE DOSE ADMINISTRATION OF ECP TREATED CELLS PRIOR TO TRANSPLANTATION SIGNIFICANTLY INCREASES SURVIVAL IN A MHC-MISMATCHED MODEL OF ACUTE GVHD. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(2), S337-S338.
LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS RECEIVING HIGHLY PURIFIED AUTOLOGOUS CD34+THY-1+HEMATOPOIETIC STEM CELLS AFTER HIGH-DOSE CHEMOTHERAPY Mueller, A. Ms., Kohrt, H. Ek., Laport, G. G., Negrin, R. S., Cha, S., & Shizuru, J. A. (2011). LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS RECEIVING HIGHLY PURIFIED AUTOLOGOUS CD34+THY-1+HEMATOPOIETIC STEM CELLS AFTER HIGH-DOSE CHEMOTHERAPY. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(2), S198-S198.
Natural and Expanded CD4(+) CD25(+) Regulatory T Cells in Bone Marrow Transplantation Colonna, L., Sega, E. I., & Negrin, R. S. (2011). Natural and Expanded CD4(+) CD25(+) Regulatory T Cells in Bone Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(1), S58-S62.
CXCL12 Mediates Immunosuppression in the Lymphoma Microenvironment after Allogeneic Transplantation of Hematopoietic Cells Duerr, C., Pfeifer, D., Claus, R., Schmitt-Graeff, A., Gerlach, U. V., & Zeiser, R. (2010). CXCL12 Mediates Immunosuppression in the Lymphoma Microenvironment after Allogeneic Transplantation of Hematopoietic Cells. CANCER RESEARCH, 70(24), 10170-10181.
Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells Contag, C. H., Sikorski, R., Negrin, R. S., Schmidt, T., Fan, A. C., & Thorne, S. H. (2010). Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells. CANCER RESEARCH, 70(23), 9837-9845.
Definition of a Diagnostic Window Prior to the Onset of Clinically Apparent Acute Graft-Versus-Host Disease Baeuerlein, C. A., Riedel, S. S., Christian, B., Garrote, A.-L. J., Birner, A., & Beilhack, A. (2010). Definition of a Diagnostic Window Prior to the Onset of Clinically Apparent Acute Graft-Versus-Host Disease. BLOOD, 116(21), 1536-1537.
Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.
CD11B+CD11C+DENDRITIC CELLS INTERACT WITH ALLOREACTIVE T CELLS IN THE INTESTINAL MUCOSA IN ACUTE GRAFT-VERSUS-HOST DISEASE Garrote, A. Lj., Brede, C., Baeuerlein, C., Riedel, S., Kiesel, C., & Schulz, S. (2010). CD11B+CD11C+DENDRITIC CELLS INTERACT WITH ALLOREACTIVE T CELLS IN THE INTESTINAL MUCOSA IN ACUTE GRAFT-VERSUS-HOST DISEASE. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 480-480.
DIFFERENCES IN ALLOREACTIVE T CELL MIGRATION IN MHC MATCHED VERSUS MHC MISMATCHED HCT ARE CAUSED BY WAVES OF T CELL EXPANSION Baeuerlein, C., Riedel, S., Brede, C., Garrote, A. Lj., Kiesel, C., & Beilhack, A. (2010). DIFFERENCES IN ALLOREACTIVE T CELL MIGRATION IN MHC MATCHED VERSUS MHC MISMATCHED HCT ARE CAUSED BY WAVES OF T CELL EXPANSION. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 479-479.
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects Olson, J. A., Leveson-Gower, D. B., Gill, S., Baker, J., Beilhack, A., & Negrin, R. S. (2010). NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. BLOOD, 115(21), 4293-4301.
Biology and clinical effects of natural killer cells in allogeneic transplantation Benjamin, J. E., Gill, S., & Negrin, R. S. (2010). Biology and clinical effects of natural killer cells in allogeneic transplantation. CURRENT OPINION IN ONCOLOGY, 22(2), 130-137.
CD107 surface mobilization of peripheral blood T-cells to predict acute graft-versus-host disease Baeuerlin, C. A., Brede, C., Riedel, S. S., Garrote, A. J., Kiesel, C., & Beilhack, A. (2010). CD107 surface mobilization of peripheral blood T-cells to predict acute graft-versus-host disease. BONE MARROW TRANSPLANTATION, 45, S117-S117.
Simultaneous blockade of several endothelial ligands is required to prevent alloreactive T-cell trafficking to target tissues Beilhack, A., Baker, J., Riedel, S., Brede, C., Baeuerlein, C. A., & Schulz, S. (2010). Simultaneous blockade of several endothelial ligands is required to prevent alloreactive T-cell trafficking to target tissues. BONE MARROW TRANSPLANTATION, 45, S15-S15.
Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., & Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303-309.
Immunoglobulin G Fc Receptor Fc gamma RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma Weng, W.-K., Negrin, R. S., Lavori, P., & Horning, S. J. (2010). Immunoglobulin G Fc Receptor Fc gamma RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 28(2), 279-284.
Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells Zangi, L., Margalit, R., Reich-Zeliger, S., Bachar-Lustig, E., Beilhack, A., & Reisner, Y. (2009). Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells. STEM CELLS, 27(11), 2865-2874.
Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation Olson, J. A., Zeiser, R., Beilhack, A., Goldman, J. J., & Negrin, R. S. (2009). Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation. JOURNAL OF IMMUNOLOGY, 183(5), 3219-3228.
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.
Natural Killer Cells in Allogeneic Transplantation: Effect on Engraftment, Graft- versus-Tumor, and Graft-versus-Host Responses Gill, S., Olson, J. A., & Negrin, R. S. (2009). Natural Killer Cells in Allogeneic Transplantation: Effect on Engraftment, Graft- versus-Tumor, and Graft-versus-Host Responses. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(7), 765-776.
Regulation of different inflammatory diseases by impacting the mevalonate pathway Zeiser, R., Maas, K., Youssef, S., Duerr, C., Steinman, L., & Negrin, R. S. (2009). Regulation of different inflammatory diseases by impacting the mevalonate pathway. IMMUNOLOGY, 127(1), 18-25.
Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation Abrahamsson, A. E., Geron, I., Gotlib, J., Dao, K.-H. T., Barroga, C. F., & Jamieson, C. Hm. (2009). Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(10), 3925-3929.
Follicular lymphoma B cells induce the conversion of conventional CD4(+) T cells to T-regulatory cells Ai, W. Z., Hou, L.-Z., Zeiser, R., Czerwinski, D., Negrin, R. S., & Levy, R. (2009). Follicular lymphoma B cells induce the conversion of conventional CD4(+) T cells to T-regulatory cells. INTERNATIONAL JOURNAL OF CANCER, 124(1), 239-244.
Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation Reichardt, W., Duerr, C., von Elverfeldt, D., Juettner, E., Gerlach, U. V., & Zeiser, R. (2008). Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. JOURNAL OF IMMUNOLOGY, 181(7), 4770-4779.
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity Nishimura, R., Baker, J., Beilhack, A., Zeiser, R., Olson, J. A., & Negrin, R. S. (2008). In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. BLOOD, 112(6), 2563-2574.
Plasmacytoid dendritic cells take up opsonized antigen leading to CD4(+) and CD8(+) T cell activation in vivo Bjorck, P., Beilhack, A., Herman, E. I., Negrin, R. S., & Engleman, E. G. (2008). Plasmacytoid dendritic cells take up opsonized antigen leading to CD4(+) and CD8(+) T cell activation in vivo. JOURNAL OF IMMUNOLOGY, 181(6), 3811-3817.
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen Laport, G. G., Alvarnas, J. C., Palmer, J. M., Snyder, D. S., Slovak, M. L., & Forman, S. J. (2008). Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. BLOOD, 112(3), 903-909.
Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience Chen, A. I., McMillan, A., Neprin, R. S., Horning, S. J., & Laport, G. G. (2008). Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14(7), 741-747.
Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs Beilhack, A., Schulz, S., Baker, J., Beilhack, G. F., Nishimura, R., & Negrin, R. S. (2008). Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. BLOOD, 111(5), 2919-2928.
Interleukin-2 receptor downstream events in regulatory T cells - Implications for the choice of immunosuppressive drug therapy Zeiser, R., & Negrin, R. S. (2008). Interleukin-2 receptor downstream events in regulatory T cells - Implications for the choice of immunosuppressive drug therapy. CELL CYCLE, 7(4), 458-462.
The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation Nguyen, V. H., Shashidhar, S., Chang, D. S., Ho, L., Kambham, N., & Negrin, R. S. (2008). The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. BLOOD, 111(2), 945-953.
Differential impact of mammalian target of rapamycin inhibition on CD4(+)CD25(+)Foxp3(+) regulatory T cells compared with conventional CD4(+) T cells Zeiser, R., Leveson-Gower, D. B., Zambricki, E. A., Kambham, N., Beilhack, A., & Negrin, R. S. (2008). Differential impact of mammalian target of rapamycin inhibition on CD4(+)CD25(+)Foxp3(+) regulatory T cells compared with conventional CD4(+) T cells. BLOOD, 111(1), 453-462.
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity Zeiser, R., Youssef, S., Baker, J., Kambham, N., Steinman, L., & Negrin, R. S. (2007). Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. BLOOD, 110(13), 4588-4598.
Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease Zeiser, R., Zambricki, E. A., Leveson-Gower, D., Kambham, N., Beilhack, A., & Negrin, R. S. (2007). Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 13(12), 1427-1438.
A novel technique for the enrichment of primary ovarian cancer cells Chan, J. K., Hamilton, C. A., Anderson, E. M., Cheung, M. K., Baker, J., & Negrin, R. S. (2007). A novel technique for the enrichment of primary ovarian cancer cells. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 197(5).
CD101 surface expression discriminates potency among murine FoxP3(+) regulatory T cells Fernandez, I., Zeiser, R., Karsunky, H., Kambham, N., Beilhack, A., & Engleman, E. (2007). CD101 surface expression discriminates potency among murine FoxP3(+) regulatory T cells. JOURNAL OF IMMUNOLOGY, 179(5), 2808-2814.
In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation Nguyen, V. H., Zeiser, R., daSilva, D. L., Chang, D. S., Beilhack, A., & Negrin, R. S. (2007). In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. BLOOD, 109(6), 2649-2656.
Early CD30 signaling is critical for adoptively transferred CD4(+)CD25(+) regulatory T cells in prevention of acute graft-versus-host disease Zeiser, R., Nguyen, V. H., Hou, J.-Z., Beilhack, A., Zambricki, E., & Negrin, R. S. (2007). Early CD30 signaling is critical for adoptively transferred CD4(+)CD25(+) regulatory T cells in prevention of acute graft-versus-host disease. BLOOD, 109(5), 2225-2233.
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Oehler, V. G., Gooley, T., Snyder, D. S., Johnston, L., Lin, A., & Radich, J. P. (2007). The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. BLOOD, 109(4), 1782-1789.
Promise and challenges of human regulatory T cells in the clinic Negrin, R. S., & Hou, J.-Z. (2007). Promise and challenges of human regulatory T cells in the clinic. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 13(1), 12-16.
Alloreactive T-cell trafficking after hematopoietic stem cell transplantation. Beilhack, A., Schulz, S., Baker, J., Beilhack, G., Herman, E., & Negrin, R. (2007). Alloreactive T-cell trafficking after hematopoietic stem cell transplantation. Journal of stem cells & regenerative medicine, 2(1), 107-?.
Alloreactive T-cell trafficking after hematopoietic stem cell transplantation. Beilhack, A., Schulz, S., Baker, J., Beilhack, G., Herman, E., & Negrin, R. (2007). Alloreactive T-cell trafficking after hematopoietic stem cell transplantation. Journal of stem cells & regenerative medicine, 2(1), 17-?.
Role of naturally arising regulatory T cells in hematopoietic cell transplantation Nguyen, V. H., Zeiser, R., & Negrin, R. S. (2006). Role of naturally arising regulatory T cells in hematopoietic cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(10), 995-1009.
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., & Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703-711.
Inhibition of CD4(+)CD25(+) regulatory T-cell function by calcineurin-dependent interleukin-2 production Zeiser, R., Nguyen, V. H., Beilhack, A., Buess, M., Schulz, S., & Negrin, R. S. (2006). Inhibition of CD4(+)CD25(+) regulatory T-cell function by calcineurin-dependent interleukin-2 production. BLOOD, 108(1), 390-399.
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Negrin, R. S., & Contag, C. H. (2006). In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Nature reviews. Immunology, 6(6), 484-490.
Innovation - In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease Negrin, R. S., & Contag, C. H. (2006). Innovation - In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. NATURE REVIEWS IMMUNOLOGY, 6(6), 484-U2.
Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation. Zeiser, R., Beilhack, A., & Negrin, R. S. (2006). Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation. Current stem cell research & therapy, 1(2), 203-212.
Synergistic antitumor effects of immune cell-viral biotherapy Thorne, S. H., Negrin, R. S., & Contag, C. H. (2006). Synergistic antitumor effects of immune cell-viral biotherapy. SCIENCE, 311(5768), 1780-1784.
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study Chan, J. K., Hamilton, C. A., Cheung, M. K., Karimi, M., Baker, J., & Negrin, R. S. (2006). Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study. CLINICAL CANCER RESEARCH, 12(6), 1859-1867.
The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab Kornacker, M., Verneris, M. R., Kornacker, B., Ganten, T. M., Scheffold, C., & Negrin, R. S. (2006). The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab. CYTOTHERAPY, 8(1), 13-23.
Total lymphoid irradiation and transplantation tolerance Lowsky, R., & Negrin, R. S. (2006). Total lymphoid irradiation and transplantation tolerance. CURRENT OPINION IN ORGAN TRANSPLANTATION, 11(1), 54-61.
Protective conditioning for acute graft-versus-host disease - Reply Lowsky, R., Negrin, R. S., & Strober, S. (2005). Protective conditioning for acute graft-versus-host disease - Reply. NEW ENGLAND JOURNAL OF MEDICINE, 353(25), 2718-2718.
Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8(+) T cells and NK cells Karimi, M., Cao, T. M., Baker, J. A., Verneris, M. R., Soares, L., & Negrin, R. S. (2005). Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8(+) T cells and NK cells. JOURNAL OF IMMUNOLOGY, 175(12), 7819-7828.
Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation Schimmelpfennig, C. H., Schulz, S., Arber, C., Baker, J., Tarner, I., & Negrin, R. S. (2005). Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation. AMERICAN JOURNAL OF PATHOLOGY, 167(5), 1321-1331.
Protective conditioning for acute graft-versus-host disease Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., & Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321-1331.
In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets Beilhack, A., Schulz, S., Baker, J., Beilhack, G. F., Wieland, C. B., & Negrin, R. S. (2005). In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. BLOOD, 106(3), 1113-1122.
Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation Cao, Y. A., Bachmann, M. H., Beilhack, A., Yang, Y., Tanaka, M., & Contag, C. H. (2005). Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. TRANSPLANTATION, 80(1), 134-139.
Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells Verneris, M. R., Arshi, A., Edinger, M., Kornacker, M., Natkunam, Y., & Negrin, R. S. (2005). Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. CLINICAL CANCER RESEARCH, 11(12), 4561-4570.
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma Leemhuis, T., Wells, S., Scheffold, C., Edinger, M., & Negrin, R. S. (2005). A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(3), 181-187.
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Oehler, V. G., Radich, J. P., Storer, I., Blume, K. G., Chauncey, T., & Bensinger, W. (2005). Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(2), 85-92.
Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system Shizuru, J. A., Negrin, R. S., & Weissman, I. L. (2005). Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system. ANNUAL REVIEW OF MEDICINE, 56, 509-538.
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8(+) T cells Verneris, M. R., Karami, M., Baker, J., Jayaswal, A., & Negrin, R. S. (2004). Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8(+) T cells. BLOOD, 103(8), 3065-3072.
Evaluation of effector cell fate and function by in vivo bioluminescence imaging Edinger, M., Hoffmann, P., Contag, C. H., & Negrin, R. S. (2003). Evaluation of effector cell fate and function by in vivo bioluminescence imaging. METHODS, 31(2), 172-179.
CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C. G., & Negrin, R. S. (2003). CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. NATURE MEDICINE, 9(9), 1144-1150.
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging Edinger, M., Cao, Y. A., Verneris, M. R., Bachmann, M. H., Contag, C. H., & Negrin, R. S. (2003). Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. BLOOD, 101(2), 640-648.
Advancing animal models of neoplasia through in vivo bioluminescence imaging Edinger, M., Cao, Y. A., Hornig, Y. S., Jenkins, D. E., Verneris, M. R., & Contag, C. H. (2002). Advancing animal models of neoplasia through in vivo bioluminescence imaging. EUROPEAN JOURNAL OF CANCER, 38(16), 2128-2136.
Visualization of effective tumor targeting by CD8+natural killer T cells redirected with bispecific antibody F(ab ')(2)HER2xCD3 Scheffold, C., Kornacker, M., Scheffold, Y. C., Contag, C. H., & Negrin, R. S. (2002). Visualization of effective tumor targeting by CD8+natural killer T cells redirected with bispecific antibody F(ab ')(2)HER2xCD3. CANCER RESEARCH, 62(20), 5785-5791.
Studies of ex vivo activated and expanded CD8(+) NK-T cells in humans and mice Verneris, M. R., Baker, J., Edinger, M., & Negrin, R. S. (2002). Studies of ex vivo activated and expanded CD8(+) NK-T cells in humans and mice. JOURNAL OF CLINICAL IMMUNOLOGY, 22(3), 131-136.
Understanding immune cell trafficking patterns via in vivo bioluminescence imaging Mandl, S., Schimmelpfennig, C., Edinger, M., Negrin, R. S., & Contag, C. H. (2002). Understanding immune cell trafficking patterns via in vivo bioluminescence imaging. JOURNAL OF CELLULAR BIOCHEMISTRY, 239-248.
Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence Negrin, R. S., Edinger, M., Verneris, M., Cao, Y. A., Bachmann, M., & Contag, C. H. (2002). Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence. ANNALS OF HEMATOLOGY, 81, S44-S45.
Bioluminescence imaging of lymphocyte trafficking in vivo Hardy, J., Edinger, M., Bachmann, M. H., Negrin, R. S., Fathman, C. G., & Contag, C. H. (2001). Bioluminescence imaging of lymphocyte trafficking in vivo. EXPERIMENTAL HEMATOLOGY, 29(12), 1353-1360.
Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis Kornacker, M., Schlattner, U., Wallimann, T., Verneris, M. R., Negrin, R. S., & Wolf, J. (2001). Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis. INTERNATIONAL JOURNAL OF CANCER, 94(4), 513-519.
Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+cells in patients with advanced hematologic malignancies Cao, T. M., Kusnierz-Glaz, C., Valone, F., Stockerl-Goldstein, K. E., Hu, W. W., & Negrin, R. S. (2001). Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+cells in patients with advanced hematologic malignancies. CANCER, 91(12), 2205-2213.
Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A., & Negrin, R. S. (2001). Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. BLOOD, 97(10), 2923-2931.
Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells Kornacker, M., Verneris, M. R., Kornacker, B., Scheffold, C., & Negrin, R. S. (2001). Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. IMMUNOLOGY LETTERS, 76(3), 169-173.
CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56(+) T cells Lopez, R. D., Waller, E. K., Lu, P. H., & Negrin, R. S. (2001). CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56(+) T cells. CANCER IMMUNOLOGY IMMUNOTHERAPY, 49(12), 629-640.
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. Bensinger, W. I., Martin, P. J., Storer, B., Clift, R., Forman, S. J., & Blume, K. (2001). Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. NEW ENGLAND JOURNAL OF MEDICINE, 344(3), 175-181.
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial Horning, S. J., Negrin, R. S., Hoppe, R. T., Rosenberg, S. A., Chao, N. J., & Blume, K. G. (2001). High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. BLOOD, 97(2), 404-409.
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., & Stockerl-Goldstein, K. (2001). High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(5), 294-301.
Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation Alvarnas, J. C., Linn, Y. C., Hope, E. G., & Negrin, R. S. (2001). Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(4), 216-222.
CD31 mismatching affects marrow transplantation outcome GRUMET, F. C., Hiraki, D. D., Brown, B. W., Zehnder, J. L., Zacks, E. S., & Negrin, R. S. (2001). CD31 mismatching affects marrow transplantation outcome. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(9), 503-512.
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease Stuart, M. J., Chao, N. S., Horning, S. J., Wong, R. M., Negrin, R. S., & Goldstein, S. (2001). Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 552-560.
Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma Verneris, M. R., Ito, M., Baker, E., Arshi, A., Negrin, R. S., & Shizuru, J. A. (2001). Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 532-542.
CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies Lopez, R. D., Xu, S., Guo, B., Negrin, R. S., & Waller, E. K. (2000). CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. BLOOD, 96(12), 3827-3837.
Resistance of ex vivo expanded CD3(+)CD56(+) T cells to Fas-mediated apoptosis Verneris, M. R., Kornacker, M., Mailander, V., & Negrin, R. S. (2000). Resistance of ex vivo expanded CD3(+)CD56(+) T cells to Fas-mediated apoptosis. CANCER IMMUNOLOGY IMMUNOTHERAPY, 49(6), 335-345.
Effect of oral glutamine supplementation during bone marrow transplantation Dickson, T. Mc., Wong, R. M., Negrin, R. S., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. E. (2000). Effect of oral glutamine supplementation during bone marrow transplantation. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 24(2), 61-66.
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., & Negrin, R. S. (2000). Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(5), 506-512.
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: Results of a prospective double-blind randomized trial Chao, N. J., Snyder, D. S., Jain, M., Wong, R. M., Niland, J. C., & Blume, K. G. (2000). Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: Results of a prospective double-blind randomized trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(3), 254-261.
A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation Nash, R. A., Kurzrock, R., DiPersio, J., Vose, J., Linker, C., & Champlin, R. (2000). A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(1), 25-34.
Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer Negrin, R. S., Atkinson, K., Leemhuis, T., Hanania, E., Juttner, C., & Klein, J. (2000). Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(3), 262-271.
Use of reporter genes for optical measurements of neoplastic disease in vivo Contag, C. H., Jenkins, D., Contag, F. R., & Negrin, R. S. (2000). Use of reporter genes for optical measurements of neoplastic disease in vivo. NEOPLASIA, 2(1-2), 41-52.
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy Hu, W. W., Negrin, R. S., Stockerl-Goldstein, K., JOHNSTON, L. J., Shizuru, J. A., & Blume, K. G. (2000). Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(1), 58-69.
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma Alvarnas, J. C., Negrin, R. S., Horning, S. J., Hu, W. W., Long, G. D., & Chao, N. J. (2000). High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(3A), 352-358.
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic tell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma Johnston, L. J., Stockerl-Goldstein, K. E., Hu, W. W., Negrin, R. S., Hoppe, R. T., & Horning, S. J. (2000). Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic tell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(5A), 555-562.
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation Cao, T. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., & Hu, W. W. (2000). Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(4), 387-394.
Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission Snyder, D. S., Nademanee, A. P., O'Donnell, M. R., Parker, P. M., Stein, A. S., & Forman, S. J. (1999). Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. LEUKEMIA, 13(12), 2053-2058.
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer Hu, W. W., Long, G. D., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Chao, N. J., & Blume, K. G. (1999). A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. CLINICAL CANCER RESEARCH, 5(11), 3411-3418.
Visualizing the kinetics of tumor-cell clearance in living animals Sweeney, T. J., Mailander, V., Tucker, A. A., Olomu, A. B., Zhang, W. S., & Contag, C. H. (1999). Visualizing the kinetics of tumor-cell clearance in living animals. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 96(21), 12044-12049.
Noninvasive assessment of tumor cell proliferation in animal models. Edinger, M., Sweeney, T. J., Tucker, A. A., Olomu, A. B., Negrin, R. S., & Contag, C. H. (1999). Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia , 1(4), 303-310.
Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Dickson, T. M., Kusnierz-Glaz, C. R., Blume, K. G., Negrin, R. S., Hu, W. W., & Stockerl-Goldstein, K. E. (1999). Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biology of blood and marrow transplantation , 5(5), 299-305.
Assays to determine hematopoietic stem cell content in blood or marrow grafts. Verfaillie, C. M., Ploemacher, R., di Persio, J., Sutherland, R., Serke, S., & Negrin, R. (1999). Assays to determine hematopoietic stem cell content in blood or marrow grafts. Cytotherapy, 1(1), 41-49.
ISHAGE Scientific Committee Report - Assays to determine hematopoietic stem cell content in blood or marrow grafts Verfaillie, C. M., Ploemacher, R., di Persio, J., Sutherland, R., Serke, S., & Negrin, R. (1999). ISHAGE Scientific Committee Report - Assays to determine hematopoietic stem cell content in blood or marrow grafts. CYTOTHERAPY, 1(1), 41-49.
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. Ross, M., Schmidt, G. M., Niland, J. C., Amylon, M. D., Dagis, A. C., & Chao, N. J. (1999). Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. Biology of blood and marrow transplantation , 5(5), 285-291.
Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice Hoyle, C., Bangs, C. D., Chang, P., Kamel, O., Mehta, B., & Negrin, R. S. (1998). Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice. BLOOD, 92(9), 3318-3327.
Minimal residual disease. Negrin, R. S. (1998). Minimal residual disease. Current opinion in hematology, 5(6), 488-493.
Engraftment of chronic myeloid leukemia in SCID mice Hoyle, C. F., & Negrin, R. S. (1998). Engraftment of chronic myeloid leukemia in SCID mice. HEMATOLOGICAL ONCOLOGY, 16(3), 87-100.
A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation Bernstein, S. H., Nademanee, A. P., Vose, J. M., Tricot, G., Fay, J. W., & Nash, R. A. (1998). A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. BLOOD, 91(9), 3509-3517.
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Long, G. D., Amylon, M. D., Stockerl-Goldstein, K. E., Negrin, R. S., Chao, N. J., & Blume, K. G. (1997). Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biology of blood and marrow transplantation , 3(6), 324-330.
Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model HELLSTROMLINDBERG, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., & Greenberg, P. (1997). Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. BRITISH JOURNAL OF HAEMATOLOGY, 99(2), 344-351.
Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation. Lu, P. H., & Negrin, R. S. (1997). Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation. Biology of blood and marrow transplantation , 3(3), 113-121.
Cellular immunotherapy and autologous transplantation for hematologic malignancy Margolin, K. A., Negrin, R. S., Wong, K. K., Chatterjee, S., Wright, C., & Forman, S. J. (1997). Cellular immunotherapy and autologous transplantation for hematologic malignancy. IMMUNOLOGICAL REVIEWS, 157, 231-240.
Granulocyte colony-stimulating factor-induced comobilization of CD4(-)CD8(-) T cells and hematopoietic progenitor cells (CD34(+)) in the blood of normal donors KUSNIERZGLAZ, C. R., Still, B. J., Amano, M., Zukor, J. D., Negrin, R. S., & Strober, S. (1997). Granulocyte colony-stimulating factor-induced comobilization of CD4(-)CD8(-) T cells and hematopoietic progenitor cells (CD34(+)) in the blood of normal donors. BLOOD, 89(7), 2586-2595.
High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Long, G. D., & Blume, K. G. (1997). High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. BLOOD, 89(3), 801-813.
Activated T cells and cytokine-induced CD3(+)CD56(+) killer cells SCHMIDTWOLF, G. D., Negrin, R. S., & SCHMIDTWOLF, I. Gh. (1997). Activated T cells and cytokine-induced CD3(+)CD56(+) killer cells. ANNALS OF HEMATOLOGY, 74(2), 51-56.
Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies KUSNIERZGLAZ, C. R., Schlegel, P. G., Wong, R. M., Schriber, J. R., Chao, N. J., & Long, G. D. (1997). Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. JOURNAL OF CLINICAL ONCOLOGY, 15(1), 18-25.
High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma Long, G. D., Chao, N. J., Hu, W. W., Negrin, R. S., Wong, R. M., & Blume, K. G. (1996). High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. CANCER, 78(12), 2502-2509.
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy Negrin, R. S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., & Greenberg, P. L. (1996). Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. BLOOD, 87(10), 4076-4081.
Leukemic burden in subpopulations of CD34(+) cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia Vandenberg, D., WESSMAN, M., Murray, L., Tong, J., Chen, B., & Hoffman, R. (1996). Leukemic burden in subpopulations of CD34(+) cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia. BLOOD, 87(10), 4348-4357.
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Chao, N. J., Parker, P. M., Niland, J. C., Wong, R. M., Dagis, A., & Blume, K. G. (1996). Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biology of blood and marrow transplantation , 2(2), 86-92.
Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Stockerl-Goldstein, K. E., Horning, S. J., Negrin, R. S., Chao, N. J., Hu, W. W., & Blume, K. G. (1996). Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biology of blood and marrow transplantation , 2(2), 76-85.
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells SCHMIDTWOLF, I. Gh., Lefterova, P., Johnston, V., Scheffold, C., Csipai, M., & Negrin, R. S. (1996). Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. CELLULAR IMMUNOLOGY, 169(1), 85-90.
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., & Levy, R. (1996). Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. CLINICAL CANCER RESEARCH, 2(3), 457-470.
Enrichment of allogeneic CD34+ cells and T cell depletion by percoll density gradient centrifugation Negrin, R. S., KUSNIERZGLAZ, C., Blume, K. G., & Strober, S. (1996). Enrichment of allogeneic CD34+ cells and T cell depletion by percoll density gradient centrifugation. BONE MARROW TRANSPLANTATION, 17, S31-S33.
BUSULFAN/CYCLOPHOSPHAMIDE AS CONDITIONING REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MYELODYSPLASIA ODONNELL, M. R., Long, G. D., Parker, P. M., Niland, J., Nademanee, A., & Forman, S. J. (1995). BUSULFAN/CYCLOPHOSPHAMIDE AS CONDITIONING REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MYELODYSPLASIA. JOURNAL OF CLINICAL ONCOLOGY, 13(12), 2973-2979.
THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE Parker, P. M., Chao, N., Nademanee, A., ODONNELL, M. R., Schmidt, G. M., & Forman, S. J. (1995). THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE. BLOOD, 86(9), 3604-3609.
2 PATHWAYS OF EXOCYTOSIS OF CYTOPLASMIC GRANULE CONTENTS AND TARGET-CELL KILLING BY CYTOKINE-INDUCED CD3(+)CD56(+) KILLER-CELLS Mehta, B. A., SCHMIDTWOLF, G. H., Weissman, I. L., & Negrin, R. S. (1995). 2 PATHWAYS OF EXOCYTOSIS OF CYTOPLASMIC GRANULE CONTENTS AND TARGET-CELL KILLING BY CYTOKINE-INDUCED CD3(+)CD56(+) KILLER-CELLS. BLOOD, 86(9), 3493-3499.
MULTIPLE CYCLES OF HIGH-DOSE CHEMOTHERAPY SUPPORTED BY HEMATOPOIETIC PROGENITOR CELLS AS TREATMENT FOR PATIENTS WITH ADVANCED MALIGNANCIES Long, G. D., Negrin, R. S., Hoyle, C. F., KUSNIERZGLAZ, C. R., Schriber, J. R., & Chao, N. J. (1995). MULTIPLE CYCLES OF HIGH-DOSE CHEMOTHERAPY SUPPORTED BY HEMATOPOIETIC PROGENITOR CELLS AS TREATMENT FOR PATIENTS WITH ADVANCED MALIGNANCIES. CANCER, 76(5), 860-868.
ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION Schriber, J. R., DEJBAKHSHJONES, S., KUSNIERZGLAZ, C. R., Ginzton, N., Still, B., & Strober, S. (1995). ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION. EXPERIMENTAL HEMATOLOGY, 23(9), 1024-1029.
TRANSPLANTATION OF ENRICHED AND PURGED PERIPHERAL-BLOOD PROGENITOR CELLS FROM A SINGLE APHERESIS PRODUCT IN PATIENTS WITH NON-HODGKINS-LYMPHOMA Negrin, R. S., KUSNIERZGLAZ, C. R., Still, B. J., Schriber, J. R., Chao, N. J., & Strober, S. (1995). TRANSPLANTATION OF ENRICHED AND PURGED PERIPHERAL-BLOOD PROGENITOR CELLS FROM A SINGLE APHERESIS PRODUCT IN PATIENTS WITH NON-HODGKINS-LYMPHOMA. BLOOD, 85(11), 3334-3341.
IS NITROUS-OXIDE SAFE FOR BONE-MARROW HARVEST Lederhaas, G., BROCKUTNE, J. G., Negrin, R. S., Riley, E., & Brodsky, J. B. (1995). IS NITROUS-OXIDE SAFE FOR BONE-MARROW HARVEST. ANESTHESIA AND ANALGESIA, 80(4), 770-772.
A NEW PREPARATORY REGIMEN FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA Chao, N. J., Kastrissios, H., Long, G. D., Negrin, R. S., Horning, S. J., & Blume, K. G. (1995). A NEW PREPARATORY REGIMEN FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA. CANCER, 75(6), 1354-1359.
ENRICHMENT OF HUMAN HEMATOPOIETIC STEM-CELL ACTIVITY IN THE CD34(+)THY-1(+)LIN(-) SUBPOPULATION FROM MOBILIZED PERIPHERAL-BLOOD Murray, L., Chen, B., Galy, A., Chen, S., Tushinski, R., & Tsukamoto, A. (1995). ENRICHMENT OF HUMAN HEMATOPOIETIC STEM-CELL ACTIVITY IN THE CD34(+)THY-1(+)LIN(-) SUBPOPULATION FROM MOBILIZED PERIPHERAL-BLOOD. BLOOD, 85(2), 368-378.
EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES Nagler, A., MacKichan, M. L., Negrin, R. S., Donlon, T., & Greenberg, P. L. (1995). EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 9(1), 30-39.
FRACTIONATED TOTAL-BODY IRRADIATION, ETOPOSIDE, AND CYCLOPHOSPHAMIDE PLUS AUTOGRAFTING IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA Horning, S. J., Negrin, R. S., Chao, N. J., Long, G. D., Hoppe, R. T., & Blume, K. G. (1994). FRACTIONATED TOTAL-BODY IRRADIATION, ETOPOSIDE, AND CYCLOPHOSPHAMIDE PLUS AUTOGRAFTING IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA. JOURNAL OF CLINICAL ONCOLOGY, 12(12), 2552-2558.
GRANULOCYTE-COLONY-STIMULATING FACTOR AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION Schriber, J. R., Chao, N. J., Long, G. D., Negrin, R. S., Tierney, D. K., & Blume, K. G. (1994). GRANULOCYTE-COLONY-STIMULATING FACTOR AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION. BLOOD, 84(5), 1680-1684.
FRACTIONATED TOTAL-BODY IRRADIATION AND HIGH-DOSE ETOPOSIDE AS A PREPARATORY REGIMEN FOR BONE-MARROW TRANSPLANTATION FOR 94 PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE Snyder, D. S., Negrin, R. S., ODONNELL, M. R., Chao, N. J., Amylon, M. D., & Blume, K. G. (1994). FRACTIONATED TOTAL-BODY IRRADIATION AND HIGH-DOSE ETOPOSIDE AS A PREPARATORY REGIMEN FOR BONE-MARROW TRANSPLANTATION FOR 94 PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE. BLOOD, 84(5), 1672-1679.
A NOVEL POPULATION OF EXPANDED HUMAN CD3+CD56+ CELLS DERIVED FROM T-CELLS WITH POTENT IN-VIVO ANTITUMOR-ACTIVITY IN MICE WITH SEVERE COMBINED IMMUNODEFICIENCY Lu, P. H., & Negrin, R. S. (1994). A NOVEL POPULATION OF EXPANDED HUMAN CD3+CD56+ CELLS DERIVED FROM T-CELLS WITH POTENT IN-VIVO ANTITUMOR-ACTIVITY IN MICE WITH SEVERE COMBINED IMMUNODEFICIENCY. JOURNAL OF IMMUNOLOGY, 153(4), 1687-1696.
PROPAGATION OF LARGE NUMBERS OF T-CELLS WITH NATURAL-KILLER-CELL MARKERS SCHMIDTWOLF, I. Gh., Lefterova, P., Johnston, V., Huhn, D., Blume, K. G., & Negrin, R. S. (1994). PROPAGATION OF LARGE NUMBERS OF T-CELLS WITH NATURAL-KILLER-CELL MARKERS. BRITISH JOURNAL OF HAEMATOLOGY, 87(3), 453-458.
GENERATION OF T-CELLS FROM CYTOKINE-MOBILIZED PERIPHERAL-BLOOD AND ADULT BONE-MARROW CD34+ CELLS Galy, A. Hm., Webb, S., CEN, D. H., Murray, L. J., CONDINO, J., & Chen, B. P. (1994). GENERATION OF T-CELLS FROM CYTOKINE-MOBILIZED PERIPHERAL-BLOOD AND ADULT BONE-MARROW CD34+ CELLS. BLOOD, 84(1), 104-110.
A RANDOMIZED STUDY OF ERYTHROPOIETIN AND GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) VERSUS PLACEBO AND G-CSF FOR PATIENTS WITH HODGKINS AND NON-HODGKINS-LYMPHOMA UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION Chao, N. J., Schriber, J. R., Long, G. D., Negrin, R. S., CATOLICO, M., & Blume, K. G. (1994). A RANDOMIZED STUDY OF ERYTHROPOIETIN AND GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) VERSUS PLACEBO AND G-CSF FOR PATIENTS WITH HODGKINS AND NON-HODGKINS-LYMPHOMA UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION. BLOOD, 83(10), 2823-2828.
DETECTION OF TUMOR-CELLS IN PURGED BONE-MARROW AND PERIPHERAL-BLOOD MONONUCLEAR-CELLS BY POLYMERASE CHAIN-REACTION AMPLIFICATION OF BCL-2 TRANSLOCATIONS Negrin, R. S., & PESANDO, J. (1994). DETECTION OF TUMOR-CELLS IN PURGED BONE-MARROW AND PERIPHERAL-BLOOD MONONUCLEAR-CELLS BY POLYMERASE CHAIN-REACTION AMPLIFICATION OF BCL-2 TRANSLOCATIONS. JOURNAL OF CLINICAL ONCOLOGY, 12(5), 1021-1027.
THE ROLE OF N-LINKED CARBOHYDRATE RESIDUES IN LYMPHOKINE-ACTIVATED KILLER CELL-MEDIATED CYTOLYSIS Mehta, B. A., Collard, H. R., & Negrin, R. S. (1994). THE ROLE OF N-LINKED CARBOHYDRATE RESIDUES IN LYMPHOKINE-ACTIVATED KILLER CELL-MEDIATED CYTOLYSIS. CELLULAR IMMUNOLOGY, 155(1), 95-110.
MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES Neubauer, A., Greenberg, P., Negrin, R., Ginzton, N., & Liu, E. (1994). MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 8(4), 638-641.
ROLE OF ETOPOSIDE (VP-16) IN PREPARATORY REGIMENS FOR PATIENTS WITH LEUKEMIA OR LYMPHOMA UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION Blume, K. G., Long, G. D., Negrin, R. S., Chao, N. J., KUSNIERZGLAZ, C., & Amylon, M. D. (1994). ROLE OF ETOPOSIDE (VP-16) IN PREPARATORY REGIMENS FOR PATIENTS WITH LEUKEMIA OR LYMPHOMA UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION. BONE MARROW TRANSPLANTATION, 14, S9-S10.
ANALYSIS OF HUMAN HEMATOPOIETIC STEM-CELL POPULATIONS Murray, L., DiGiusto, D., Chen, B., Chen, S., Combs, J., & Tsukamoto, A. (1994). ANALYSIS OF HUMAN HEMATOPOIETIC STEM-CELL POPULATIONS. BLOOD CELLS, 20(2-3), 364-370.
PHENOTYPIC CHARACTERIZATION AND IDENTIFICATION OF EFFECTOR-CELLS INVOLVED IN TUMOR-CELL RECOGNITION OF CYTOKINE-INDUCED KILLER-CELLS SCHMIDTWOLF, I. Gh., Lefterova, P., Mehta, B. A., Fernandez, L. P., HUHN, L. D., & Negrin, R. S. (1993). PHENOTYPIC CHARACTERIZATION AND IDENTIFICATION OF EFFECTOR-CELLS INVOLVED IN TUMOR-CELL RECOGNITION OF CYTOKINE-INDUCED KILLER-CELLS. EXPERIMENTAL HEMATOLOGY, 21(13), 1673-1679.
FRACTIONATED TOTAL-BODY IRRADIATION AND HIGH-DOSE ETOPOSIDE AS A PREPARATORY REGIMEN FOR BONE-MARROW TRANSPLANTATION FOR 99 PATIENTS WITH ACUTE-LEUKEMIA IN 1ST COMPLETE REMISSION Snyder, D. S., Chao, N. J., Amylon, M. D., Taguchi, J., Long, G. D., & Blume, K. G. (1993). FRACTIONATED TOTAL-BODY IRRADIATION AND HIGH-DOSE ETOPOSIDE AS A PREPARATORY REGIMEN FOR BONE-MARROW TRANSPLANTATION FOR 99 PATIENTS WITH ACUTE-LEUKEMIA IN 1ST COMPLETE REMISSION. BLOOD, 82(9), 2920-2928.
EFFICIENT GENERATION AND CHARACTERIZATION OF TUMOR-CELL SUBCLONES WITH DIFFERENT ADHESION PATHWAYS INVOLVED IN CELL-LYSIS Lefterova, P., Negrin, R., Neubauer, A., Huhn, D., Blume, K., & SCHMIDTWOLF, I. (1993). EFFICIENT GENERATION AND CHARACTERIZATION OF TUMOR-CELL SUBCLONES WITH DIFFERENT ADHESION PATHWAYS INVOLVED IN CELL-LYSIS. HAEMATOLOGICA, 78(6), 353-358.
CYCLOSPORINE, METHOTREXATE, AND PREDNISONE COMPARED WITH CYCLOSPORINE AND PREDNISONE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE Chao, N. J., Schmidt, G. M., Niland, J. C., Amylon, M. D., Dagis, A. C., & Forman, S. J. (1993). CYCLOSPORINE, METHOTREXATE, AND PREDNISONE COMPARED WITH CYCLOSPORINE AND PREDNISONE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE. NEW ENGLAND JOURNAL OF MEDICINE, 329(17), 1225-1230.
THE EFFICACY OF GRANULOCYTE-COLONY-STIMULATING FACTOR FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA WITH MONOCLONAL-ANTIBODY PURGED BONE-MARROW Schriber, J. R., Negrin, R. S., Chao, N. J., Long, G. D., Horning, S. J., & Blume, K. G. (1993). THE EFFICACY OF GRANULOCYTE-COLONY-STIMULATING FACTOR FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA WITH MONOCLONAL-ANTIBODY PURGED BONE-MARROW. LEUKEMIA, 7(10), 1491-1495.
TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN Negrin, R. S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., & Greenberg, P. L. (1993). TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN. BLOOD, 82(3), 737-743.
USE AND TOXICITY OF THE COLONY-STIMULATING FACTORS Schriber, J. R., & Negrin, R. S. (1993). USE AND TOXICITY OF THE COLONY-STIMULATING FACTORS. DRUG SAFETY, 8(6), 457-468.
GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS ACCELERATE GRANULOCYTE AND PLATELET RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY Chao, N. J., Schriber, J. R., Grimes, K., Long, G. D., Negrin, R. S., & Blume, K. G. (1993). GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS ACCELERATE GRANULOCYTE AND PLATELET RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY. BLOOD, 81(8), 2031-2035.
BUSULFAN ETOPOSIDE - INITIAL EXPERIENCE WITH A NEW PREPARATORY REGIMEN FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NONLYMPHOBLASTIC LEUKEMIA Chao, N. J., Stein, A. S., Long, G. D., Negrin, R. S., Amylon, M. D., & Blume, K. G. (1993). BUSULFAN ETOPOSIDE - INITIAL EXPERIENCE WITH A NEW PREPARATORY REGIMEN FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NONLYMPHOBLASTIC LEUKEMIA. BLOOD, 81(2), 319-323.
THE USE OF COLONY STIMULATING FACTORS IN CLINICAL BONE-MARROW TRANSPLANTATION Negrin, R. S., & Greenberg, P. L. (1992). THE USE OF COLONY STIMULATING FACTORS IN CLINICAL BONE-MARROW TRANSPLANTATION. CURRENT OPINION IN IMMUNOLOGY, 4(5), 567-570.
DYNAMIC ASSESSMENT OF QUALITY-OF-LIFE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION Chao, N. J., Tierney, D. K., Bloom, J. R., Long, G. D., Barr, T. A., & Blume, K. G. (1992). DYNAMIC ASSESSMENT OF QUALITY-OF-LIFE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION. BLOOD, 80(3), 825-830.
G-CSF AND PERIPHERAL-BLOOD PROGENITOR CELLS Chao, N. J., Long, G. D., Negrin, R. S., Schriber, J. R., RAIMONDI, C. M., & Blume, K. G. (1992). G-CSF AND PERIPHERAL-BLOOD PROGENITOR CELLS. LANCET, 339(8806), 1410-1410.
Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging. Negrin, R. S. (1992). Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging. Journal of hematotherapy, 1(4), 361-368.
INVITRO AND INVIVO ACTIVITY OF MURINE LYMPHOKINE-ACTIVATED KILLER-CELLS AFTER CRYOPRESERVATION SCHMIDTWOLF, I. Gh., Aihara, M., Negrin, R. S., Blume, K. G., & Chao, N. J. (1992). INVITRO AND INVIVO ACTIVITY OF MURINE LYMPHOKINE-ACTIVATED KILLER-CELLS AFTER CRYOPRESERVATION. TRANSFUSION, 32(1), 42-45.
Therapy of hematopoietic disorders with recombinant colony-stimulating factors. Negrin, R. S., & Greenberg, P. L. (1992). Therapy of hematopoietic disorders with recombinant colony-stimulating factors. Advances in pharmacology (San Diego, Calif.), 23, 263-296.
USE OF A SCID MOUSE HUMAN LYMPHOMA MODEL TO EVALUATE CYTOKINE-INDUCED KILLER-CELLS WITH POTENT ANTITUMOR CELL-ACTIVITY SCHMIDTWOLF, I. Gh., Negrin, R. S., Kiem, H. P., Blume, K. G., & Weissman, I. L. (1991). USE OF A SCID MOUSE HUMAN LYMPHOMA MODEL TO EVALUATE CYTOKINE-INDUCED KILLER-CELLS WITH POTENT ANTITUMOR CELL-ACTIVITY. JOURNAL OF EXPERIMENTAL MEDICINE, 174(1), 139-149.
USE OF THE POLYMERASE CHAIN-REACTION TO MONITOR THE EFFECTIVENESS OF EX VIVO TUMOR-CELL PURGING Negrin, R. S., Kiem, H. P., SCHMIDTWOLF, I. Gh., Blume, K. G., & Cleary, M. L. (1991). USE OF THE POLYMERASE CHAIN-REACTION TO MONITOR THE EFFECTIVENESS OF EX VIVO TUMOR-CELL PURGING. BLOOD, 77(3), 654-660.
THE STANFORD EXPERIENCE WITH HIGH-DOSE ETOPOSIDE CYTOREDUCTIVE REGIMENS AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA - PRELIMINARY DATA Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Kwak, L. W., & Blume, K. G. (1991). THE STANFORD EXPERIENCE WITH HIGH-DOSE ETOPOSIDE CYTOREDUCTIVE REGIMENS AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA - PRELIMINARY DATA. ANNALS OF ONCOLOGY, 2, 47-50.
IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF Nagler, A., Binet, C., MacKichan, M. L., Negrin, R., Bangs, C., & Greenberg, P. (1990). IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF. BLOOD, 76(7), 1299-1307.
MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR Negrin, R. S., HAEUBER, D. H., Nagler, A., Kobayashi, Y., Sklar, J., & Greenberg, P. L. (1990). MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR. BLOOD, 76(1), 36-43.
EFFECTS OF CSFS IN PRELEUKEMIA Greenberg, P. L., Negrin, R., & Nagler, A. (1990). EFFECTS OF CSFS IN PRELEUKEMIA. BONE MARROW TRANSPLANTATION, 6, 121-126.
EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES Nagler, A., Ginzton, N., Negrin, R., Bang, D., Donlon, T., & Greenberg, P. (1990). EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 4(3), 193-202.
Bone marrow transplantation for hematologic malignancies: the Stanford experience. Chao, N. J., Amylon, M. D., Long, G. D., Negrin, R. S., Hoppe, R. T., & Blume, K. G. (1990). Bone marrow transplantation for hematologic malignancies: the Stanford experience. Clinical transplants, 157-163.
EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR Greenberg, P., Negrin, R., Nagler, A., Vincent, M., & Donlon, T. (1990). EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR. INTERNATIONAL JOURNAL OF CELL CLONING, 8, 293-302.
THE USE OF HEMATOPOIETIC GROWTH-FACTORS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES Greenberg, P. L., Negrin, R., & Nagler, A. (1990). THE USE OF HEMATOPOIETIC GROWTH-FACTORS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES. CANCER SURVEYS, 9(1), 199-212.
EFFECTS OF TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR Greenberg, P., Negrin, R., Nagler, A., Souza, L., & Donlon, T. (1990). EFFECTS OF TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR. HEMATOPOIETIC GROWTH FACTORS IN TRANSFUSION MEDICINE, 338, 151-161.
LYMPHOKINE-ACTIVATED KILLER CELL-ACTIVITY AFTER CRYOPRESERVATION SCHMIDTWOLF, I. Gh., Aihara, M., Negrin, R. S., Blume, K. G., & Chao, N. J. (1989). LYMPHOKINE-ACTIVATED KILLER CELL-ACTIVITY AFTER CRYOPRESERVATION. JOURNAL OF IMMUNOLOGICAL METHODS, 125(1-2), 185-189.
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL Negrin, R. S., HAEUBER, D. H., Nagler, A., Olds, L. C., Donlon, T., & Greenberg, P. L. (1989). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL. ANNALS OF INTERNAL MEDICINE, 110(12), 976-984.
NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE IN ATELECTASIS Duncan, S. R., Negrin, R. S., Mihm, F. G., Guilleminault, C., & Raffin, T. A. (1987). NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE IN ATELECTASIS. CHEST, 92(4), 621-624.

View All 230 Publications

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Clinical Trials View All »

The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

4.9

Friendliness

4.9

Friendliness

4.9

Recommended to others

4.9

Recommended to others

4.9

Explanations

4.9

Explanations

4.8

Listens

4.8

Listens

4.8

Includes you in decisions

4.8

Includes you in decisions

4.9

Clear Communication

4.9

Clear Communication

4.9

Confidence in your doctor

4.9

Confidence in your doctor

4.6

Wait times

4.6

Wait times

SHC Patient, Aug 2015

Physician sets reasonable expectations.

SHC Patient, Feb 2015

Dr. Negrin is outstanding, great bedside manner. Inspires confidence, sets expectations, is clear.

SHC Patient, Feb 2015

Dr. Negrin is outstanding!

SHC Patient, Jan 2015

I have full faith that I am in the hands of a truly gifted & caring doctor.

SHC Patient, Nov 2014

Dr. Negrin is one of the finest doctors I've met. He is outstanding and caring. Excellent.

SHC Patient, Nov 2014

I was always given as much time/attenuation as I needed.

SHC Patient, Sep 2014

Dr. Negrin absolutely kind, and informative. Zoe Rabine, she is wonderful. I came to Stanford scared. I left feeling very confident in the hospital, Dr. Negrin and Zoe!

SHC Patient, Jul 2014

Care providers had their act together.

SHC Patient, Jun 2014

Best doctor at Stanford Clinic BMT Unit.

SHC Patient, May 2014

I am a Kaiser patient who lives in Los Angeles - I asked to be sent to Stanford for a SCT - so far, it has been worth the long journey.

SHC Patient, Mar 2014

Received excellent care.

SHC Patient, Dec 2013

Good!

Patient Comments

Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

SHC Patient, Aug 2015

Physician sets reasonable expectations.

SHC Patient, Feb 2015

Dr. Negrin is outstanding, great bedside manner. Inspires confidence, sets expectations, is clear.

SHC Patient, Feb 2015

Dr. Negrin is outstanding!

SHC Patient, Jan 2015

I have full faith that I am in the hands of a truly gifted & caring doctor.

SHC Patient, Nov 2014

Dr. Negrin is one of the finest doctors I've met. He is outstanding and caring. Excellent.

SHC Patient, Nov 2014

I was always given as much time/attenuation as I needed.

SHC Patient, Sep 2014

Dr. Negrin absolutely kind, and informative. Zoe Rabine, she is wonderful. I came to Stanford scared. I left feeling very confident in the hospital, Dr. Negrin and Zoe!

SHC Patient, Jul 2014

Care providers had their act together.

SHC Patient, Jun 2014

Best doctor at Stanford Clinic BMT Unit.

SHC Patient, May 2014

I am a Kaiser patient who lives in Los Angeles - I asked to be sent to Stanford for a SCT - so far, it has been worth the long journey.

SHC Patient, Mar 2014

Received excellent care.

SHC Patient, Dec 2013

Good!

New to MyHealth?

MyHealth for Mobile

WELCOME BACK

Robert Negrin

Robert Negrin

BMT specialist, Hematologist

Blood and Marrow Transplant Program (BMT)

Hematology Program

Cancer Immunotherapy Program

Practice Areas

Professional Education

Honors & Awards

Administrative Appointments

Publications

Patient Comments